Contemporary Imaging of the Renal Mass

Urologic Clinics of North America

Volumn 39, Issue 2, 2012, Pages 161-170

  Kang, Stella K ^a   Chandarana, Hersh ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CT; Diffusion weighted imaging; Dual energy CT; MRI; Renal mass; Ultrasonography

Indexed keywords

ANGIOGENESIS INHIBITOR; SORAFENIB;

ANGIOMYOLIPOMA; CANCER INVASION; CANCER STAGING; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DUAL ENERGY COMPUTED TOMOGRAPHY; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; IMAGE PROCESSING; KIDNEY CARCINOMA; KIDNEY CYST; KIDNEY INJURY; KIDNEY MASS; KIDNEY TUMOR; METASTASIS POTENTIAL; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE PLANNING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; RADIATION ATTENUATION; RENOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

CARCINOMA, RENAL CELL; CONTRAST MEDIA; CYSTS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KIDNEY DISEASES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; RADIOGRAPHIC IMAGE ENHANCEMENT; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY, DOPPLER;

EID: 84859493291     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2012.01.002     Document Type: Review

References (59)

1. Jayson M., Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998, 51:203-205.
2. Bosniak M.A. The small (< = 3.0 cm) renal parenchymal tumor: detection, diagnosis, and controversies. Radiology 1991, 179:307-317.
3. Patard J.J., Leray E., Rioux-Leclercq N., et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23(12):2763-2771.
4. Thompson R.H., Kurta J.M., Kaag M., et al. Tumor size is associated with malignant potential in renal cell carcinoma. J Urol 2009, 181(5):2033-2036.
5. Zirinsky K., Auh Y.H., Rubenstein W.A., et al. CT of the hyperdense renal cyst: sonographic correlation. AJR Am J Roentgenol 1984, 143(1):151-156.
6. Israel G.M., Bosniak M.A. How I do it: evaluating renal masses. Radiology 2005, 236:441-450.
7. Park B.K., Kim B., Kim S.H., et al. Assessment of cystic renal masses based on Bosniak classification: comparison of CT and contrast-enhanced US. Eur J Radiol 2007, 61(2):310-314.
8. Jamis-Dow C.A., Choyke P.L., Jennings S.B., et al. Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology 1996, 198:785-788.
9. Yamashita Y., Takahashi M., Watanabe O., et al. Small renal cell carcinoma: pathologic and radiologic correlation. Radiology 1992, 184(2):493-498.
10. Ruppert-Kohlmayr A.J., Uggowitzer M., Meissnitzer T., et al. Differentiation of renal clear cell carcinoma and renal papillary carcinoma using quantitative CT enhancement parameters. AJR Am J Roentgenol 2004, 183:1387-1391.
11. Zhang J., Lefkowitz R.A., Ishill N.M., et al. Solid renal cortical tumors: differentiation with CT. Radiology 2007, 244:494-504.
12. Herts B.R., Coll D.M., Novick A.C., et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR Am J Roentgenol 2002, 178:367-372.
13. Israel G.M., Hindman N., Bosniak M.A. Evaluation of cystic renal masses: comparison of CT and MR imaging by using the Bosniak classification system. Radiology 2004, 231(2):365-371.
14. Fletcher J.G., Takahashi N., Hartman R., et al. Dual-energy and dual-source CT: is there a role in the abdomen and pelvis?. Radiol Clin North Am 2009, 47(1):41-57.
15. Graser A., Becker C.R., Staehler M., et al. Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Invest Radiol 2010, 45(7):399-405.
16. Chandarana H., Megibow A.J., Cohen B.A., et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. AJR Am J Roentgenol 2011, 196(6):W693-W700.
17. Chandarana H., Block T.K., Rosenkrantz A.B., et al. Free-breathing radial 3D fat-suppressed T1-weighted gradient echo sequence: a viable alternative for contrast-enhanced liver imaging in patients unable to suspend respiration. Invest Radiol 2011, 46(10):648-653.
18. Kang S.K., Kim D., Chandarana H. Contemporary imaging of the renal mass. Curr Urol Rep 2011, 112(1):11-17.
19. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243(1):148-157.
20. Perez-Rodriguez J., Lai S., Ehst B.D., et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009, 250(2):371-377.
21. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21(4):1104-1108.
22. Kuo P., Kanal E., Abu-Alfa A.K., et al. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007, 242:647-649.
23. Ho V., Allen S., Hood M., et al. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 2002, 224:695-700.
24. Hecht E.M., Israel G.M., Krinsky G.A., et al. Renal masses: quantitative analysis of enhancement with signal intensity measurements versus qualitative analysis of enhancement with image subtraction for diagnosing malignancy at MR imaging. Radiology 2004, 232:373-378.
25. Israel G.M., Hindman N., Hecht E., et al. The use of opposed-phase chemical shift MRI in the diagnosis of renal angiomyolipomas. AJR Am J Roentgenol 2005, 184(6):1868-1872.
26. Kutikov A., Uzzo R.G. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009, 182(3):844-853.
27. Hayn M.H., Schwaab T., Underwood W., et al. RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. BJU Int 2011, 108(6):876-881.
28. Kutikov A., Smaldone M.C., Egleston B.L., et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. Eur Urol 2011, 60:241-248.
29. Narumi Y., Miyazaki T., Hatanaka Y., et al. MR imaging evaluation of renal carcinoma. Abdom Imaging 1997, 22:216-225.
30. Huchboni R.A., Debatin J.F., Krestin F.P. Contrast-enhanced MR imaging of the kidneys and adrenal glands. Magn Reson Imaging Clin N Am 1996, 4:101-131.
31. Choyke P.L., Walther M.M., Wagner J.R., et al. Renal cancer: preoperative evaluation with dual phase three-dimensional MR angiography. Radiology 1997, 205(3):767-771.
32. Kallman D.A., King B.F., Hattery R.R., et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr 1992, 16(2):240-247.
33. Sohn K.M., Lee J.M., Lee S.Y., et al. Comparing MR imaging and CT in the staging of gastric carcinoma. AJR Am J Roentgenol 2000, 174:1551-1557. [Published erratum appears in AJR Am J Roentgenol 2000;175:556].
34. Majhail N.S., Urbain J.L., Albani J.M., et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003, 21:3995-4000.
35. Chandarana H., Taouli B. Diffusion and perfusion imaging of the liver. Eur J Radiol 2010, 76(3):348-358.
36. Thoeny H.C., De Keyzer F. Diffusion-weighted MR imaging of native and transplanted kidneys. Radiology 2011, 259(1):25-38.
37. Squillaci E., Manenti G., Di Stefano F., et al. Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res 2004, 23:39-45.
38. Cova M., Squillaci E., Stacul F., et al. Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol 2004, 77:851-857.
39. Taouli B., Thakur R.K., Mannelli L., et al. Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 2009, 251:398-407.
40. Kim S., Jain M., Harris A.B., et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology 2009, 251:796-807.
41. Sandrasegaran K., Sundaram C.P., Ramaswamy R., et al. Usefulness of diffusion-weighted imaging in the evaluation of renal masses. Am J Roent 2010, 194:438-445.
42. Wang H., Cheng L., Zhang X., et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 2010, 257:135-143.
43. Rosenkrantz A.B., Niver B.E., Fitzgerald E.F., et al. Utility of the apparent diffusion coefficient for distinguishing clear cell renal cell carcinoma of low and high nuclear grade. AJR Am J Roentgenol 2010, 195:344-351.
44. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist 2008, 13(Suppl 2):4-7.
45. Smith A.D., Shah S.N., Rini B.I., et al. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010, 194(6):1470-1478.
46. Padhani A.R., Koh D.M. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011, 19:181-209.
47. Kamel I.R., Reyes D.K., Liapi E., et al. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unre hepatocellular carcinoma. J Vasc Interv Radiol 2007, 18:49-56.
48. Leary A., Pickering L.M., Larkin J.M.G., et al. Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. J Clin Oncol 2011, 29. Presented at the 2011 American Society of Clinical Oncology Annual Meeting. Chicago (IL), Supplement abstract TPS154.
49. Koh D.M., Collins D.J., Orton M.R. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011, 196(6):1351-1361.
50. Chandarana H., Lee V.S., Hecht E., et al. Comparison of biexponential and monoexponential model of diffusion weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol 2011, 46(5):285-291.
51. Le Bihan D., Breton E., Lallemand D., et al. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988, 168:497-505.
52. Le Bihan D., Breton E., Lallemand D., et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986, 161:401-407.
53. Sourbron S.P., Buckley D.L. On the scope and interpretation of the Tofts models for DCE-MRI. Magn Reson Med 2011, 66(3):735-745.
54. Sun M.R., Ngo L., Genega E.M., et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes-correlation with pathologic findings. Radiology 2009, 250:793-802.
55. Scialpi M., Di Maggio A., Midiri M., et al. Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression. AJR Am J Roentgenol 2000, 175(3):751-757.
56. Notohamiprodjo M., Sourbron S., Staehler M., et al. Measuring perfusion and permeability in renal cell carcinoma with dynamic contrast-enhanced MRI: a pilot study. J Magn Reson Imaging 2010, 31(2):490-501.
57. Hillman G.G., Singh-Gupta V., Al-Bashir A.K., et al. Dynamic contrast-enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors. Transl Oncol 2010, 3(5):293-306.
58. Galbraith S.M., Maxwell R.J., Lodge M.A., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003, 21:2831-2842.
59. Flaherty K.T., Rosen M.A., Heitjan D.F., et al. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 2008, 7(4):496-501.